Discovery and evaluation of asymmetrical monocarbonyl analogs of curcumin as anti- inflammatory agents

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 373-382

  Zhang, Yali ^a,b   Zhao, Chengguang ^a,b   He, Wenfei ^b   Wang, Zhe ^b   Fang, Qilu ^b   Xiao, Bing ^b   Liu, Zhiguo ^b   Liang, Guang ^b   Yang, Shulin ^a  

^a NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti inflammation; Inflammatory cytokines; Quantitative structure activity relationship; Sepsis

Indexed keywords

ANTIINFLAMMATORY AGENT; CURCUMIN; CURCUMIN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; SEPTIC SHOCK; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; EVALUATION STUDY; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CURCUMIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG STABILITY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898489444     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S58168     Document Type: Article

References (30)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6): 1644-1655.
2. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250-1256.
3. Verhoef J, Hustinx WM, Frasa H, et al. Issues in the adjunct therapy of severe sepsis. J Antimicrob Chemother. 1996;38(2):167-182.
4. Uji Y, Yamamoto H, Tsuchihashi H, et al. Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery. 2009;145(5):550-557.
5. London NR, Zhu W, Bozza FA, et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med. 2010;2(23):23-19.
6. Riedemann NC, Guo RF, Hollmann TJ, et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 2004;18(2):370-372.
7. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145-151.
8. Liu X, Zheng X, Wang N, et al. Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment. Br J Pharmacol. 2011;162(6):1274-1290.
9. Chen H, Qu Z, Fu L, et al. Physicochemical properties and antioxidant capacity of 3 polysaccharides from green tea, oolong tea, and black tea. J Food Sci. 2009;74(6):C469-C474.
10. Wu J, Li J, Cai Y, et al. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem. 2011;54(23):8110-8123.
11. Leitman IM. Curcumin for the prevention of acute lung injury in sepsis: is it more than the flavor of the month? J Surg Res. 2012;176(1):e5-e7.
12. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008;149(7):3549-3558.
13. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.
14. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27(4):486-494.
15. Rosemond MJ, St John-Williams L, Yamaguchi T, et al. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact. 2004;147(2):129-139.
16. Zhao C, Cai Y, He X, et al. Synthesis and anti-inflammatory evaluation of novel mono-carbonyl analogues of curcumin in LPS-stimulated RAW 264.7 macrophages. Eur J Med Chem. 2010;45(12): 5773-5780.
17. Liang G, Zhou H, Wang Y, et al. Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of curcumin. J Cell Mol Med. 2009;13(9B):3370-3379.
18. Wu J, Zhang Y, Cai Y, et al. Discovery and evaluation of piperid-4-one-containing mono-carbonyl analogs of curcumin as anti-inflammatory agents. Bioorg Med Chem. 2013;21(11):3058-3065.
19. Liang G, Li X, Chen L, et al. Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg Med Chem Lett. 2008;18(4):1525-1529.
20. Liang G, Shao L, Wang Y, et al. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem. 2009;17(6):2623-2631.
21. Roger T, Froidevaux C, Le Roy D, et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A. 2009;106(7):2348-2352.
22. Xue Y, Li H, Ung CY, et al. Classification of a diverse set of Tetrahymena pyriformis toxicity chemical compounds from molecular descriptors by statistical learning methods. Chem Res Toxicol. 2006;19(8):1030-1039.
23. Consonni V, Todeschini R, Pavan M. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. J Chem Inf Comput Sci. 2002;42(3):682-692.
24. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867-1876.
25. Xiao C, Ghosh S. NF-Kappa B, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol. 2005;560: 41-45.
26. Nelson DE, Ihekwaba AE, Elliott M, et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science. 2004; 306(5696):704-708.
27. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol. 2008;8(11):837-848.
28. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40.
29. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322-327.
30. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92(2):689-737.